About the Conference

Oncology is a branch of science that deals with tumours and cancers. Human body is comprised of cells and each of the cell has a tightly regulated system that controls human growth, maturity, reproduction and eventual death. Cancer begins when cells in a part of the body start to grow out of control.

In most instances, patients do not acquire the antiquity of their drug or they do not care nor ought to.

Generally patients don’t think twice about how their medicine got to be the one of choice Considering the cancer treatments available today, one must be strongly reminded that those medicines didn't just appear out of nowhere. They are a result of many years of study, trials, promise, money and this entire process begins with none other than Research!

Conference Highlights:

Organ Specific Cancers.

Gynecological Cancer

Cancer Therapy and Treatment.

Cancer Diagnosis.

Role of Drugs in Cancer Prevention

Cancer Stem Cell Therapy

Pediatric Oncology

Clinical Oncology

Radiation Oncology

Surgical Oncology

Cancer Stem Cell Therapy

Cancer Prognosis and Awareness

Alternative Medicines for Cancer

Causes and Prevention of Cancer

Target Audiences:

Cancer research Students and Scientists

Cancer Researchers

Cancer research Faculty

Medical Colleges

Cancer Associations and Societies






Business Entrepreneurs

Medical Devices Manufacturing Companies

Pharmaceutical Companies

Diagnostics Companies

Benefits of joining the Conference:

Citations International affords a tremendous opportunity to join in this forum to utilize the expertise and novelties that expands the participant’s views in the field of Cancer and Oncology. We also aims to bring together front-line experts from multidisciplinary research and application areas to join this conference, to discuss the ongoing Research and Development efforts in the field of Cancer and Oncology.

Cancer and Oncology Organizations around the World:

Belgian Cancer Registry Foundation

 Bluey Day Foundation

 Cancer Association of Botswana

 Center of Molecular Immunology

 Child Cancer Foundation

 Children's Cancer Center of Lebanon

 Docrates Cancer Center

 European Cancer Organisation

 European Institute of Oncology

 European Organisation for Research and Treatment of Cancer

 European Society for Medical Oncology

 European Society of Gynaecological Oncology

 Federation of European Cancer Societies

 Friedrich Miescher Institute for Biomedical Research

 German Brain Tumour Association

 German Cancer Aid

 Global Vision Cancer Care NGO

 Help Fight Childhood Cancer

 Hong Kong Cancer Fund

 Institute of Cancer of São Paulo

 International Agency for Research on Cancer

 International Cervical Cancer Foundation

 International Society of Pediatric Oncology

 Irish Cancer Society

 Israel Cancer Research Fund

 Japan Chernobyl Foundation

 Japanese Cancer Association

 Japanese Foundation for Cancer Research

 Manchester Cancer Research Centre

 MEPs Against Cancer

 Middle East Cancer Consortium

 Nastaran Center for Cancer Prevention

 National Cancer Institute Egypt

 Norwegian Cancer Society

 Peruvian Cancer Foundation

 Programme of Action for Cancer Therapy

 Singapore Cancer Society

 Swiss Cancer Centre

 Tyler Foundation


Union for International Cancer Control Cancer – A Glimpse Statistical Analysis:

Recent analysis of cancer was 448.7 per 100,000 males and females per year. The number of deaths was 168.5 per 100,000 males and females per year. These rates are age-adjusted and based on 2009-2013 cases and deaths.

Roughly 39.0 percent of males and females will be diagnosed with cancer at certain point during their lifespan, based on data collected between 2011-2013.

In 2013, there were an estimated 14,140,254 people living with cancer in the United States.

Cancer – Survival Rate:

 Cancer survival statistics compare the survival of patients diagnosed with cancer with the survival of people in the general population who are the same age, race, and sex and who have not been diagnosed with cancer. Since these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment may differ significantly.

Gray figures represent those who have died due to cancer. Green figures represent those who have survived 5 years or more.

Recent Cases and Death rate:

It is estimated that there will be 1,685,210 new cases of cancer in 2016 and an estimated 595,690 people will die of this disease.

Who Gets This Cancer?

Statistical analysis shows that overall cancer incidence rates are higher among males than females. Among racial/ethnic groups, there are more new cases among African, American men and white women and fewer new cases among Asian/Pacific Islanders of both genders. Cancer is most often diagnosed among people aged between 65 - 74.


Number of New Cases per 100,000 Persons by Race/Ethnicity & Gender:

Who Dies From This Cancer?

Statistical analysis shows death rates for cancer are higher among the middle-aged and elderly populations. The number of deaths was 168.5 per 100,000 males and females per year based on 2009-2013 deaths.

The percent of cancer deaths is highest among people aged 75-84.

Number of Deaths per 100,000 Persons by Race/Ethnicity & Gender:

Statistical Analysis Varies over Trends:

Keeping track of the number of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.

Using statistical models for analysis, rates for new cancer of any site cases have been falling on average 1.0% each year over the last 10 years. Death rates have been falling on average 1.5% each year over 2004-2013. Age adjusted 5-year survival trends for both genders are displayed as below.

Market Growth of Cancer Research:

The global healthcare industry is witnessing a paradigm shift, skewed towards point-of-care diagnostics,

efficient treatment modalities, and personalized medication, that not solely offers proficient identification, however conjointly treats cancer conditions so as to scale back the healthcare cost and disease burden. Cancer/Tumour profiling is one such technology with the exact potential to revolutionize cancer diagnostics and therapeutics in the healthcare industry. The global cancer/tumour profiling market was valued at $13.30 billion in 2012. At the end of 2013, the market is estimated to be $14.99 billion and is poised to reach around $35 billion by 2018, growing at a CAGR of 18.50% from 2013 to 2018.